ORIC falls 32% after J&J shows early data for a rival prostate cancer drug
Why is ORIC Pharmaceuticals stock down today?
ORIC shares fell about 32% on Monday after Johnson & Johnson reported early results over the weekend for JNJ-6143, an experimental pill for the same advanced prostate cancer that ORIC's lead drug rinzimetostat targets. TIKR linked the decline to competitive concerns, citing Leerink analyst Asthika Goonewardene's view that JNJ-6143 poses a greater potential threat to rinzimetostat. The two drugs have not been compared directly in a clinical trial.
- Move
- ▼ 32%
- Price
- $13.17 → $8.96
- Value lost
- ~$0.44B
- J&J tumor response rate
- 75% (12 of 16)
- ORIC cash, June 30
- $387.6M
- Value before the drop
- ~$1.37B
Prices: closing price, Oct 26, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean
ORIC closed at $8.96 on Oct 26, 2026, versus $13.17 on Oct 23, according to Stock Analysis.
Snapshot at the Oct 26, 2026 close
- Market value
- $929M
- Cash and investments
- $388M
- Enterprise value
- $541M
- Cash use per quarter
- $28M
- Price/sales
- n/m
- P/E
- n/m
Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 3, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $8.96; 103.7 million shares (common shares on the cover page of the 10-Q filed Aug 3, 2026). n/m = not meaningful (e.g. negative earnings).
Why ORIC fell
ORIC fell on the first trading day after Johnson & Johnson reported early results with high response rates for a rival drug in the same prostate cancer; the coverage we found tied the drop to that competition, citing Leerink’s view that J&J’s drug is a bigger threat to ORIC’s lead drug, rinzimetostat.
- J&J presented Phase 1 results for JNJ-6143 at the European Society for Medical Oncology (ESMO) congress in Madrid on Saturday, Oct 24, and issued its press release on Sunday, Oct 25. JNJ-6143 is a once-daily pill for metastatic prostate cancer that keeps growing despite hormone-blocking drugs, the disease rinzimetostat is in a Phase 3 trial for.
- At the dose J&J chose for further testing, tumors shrank in 12 of 16 patients whose tumors could be measured (75%), J&J said.
- TIKR reported on Oct 26 that Leerink analyst Asthika Goonewardene called the J&J data “immaculate” and said the results “dial up the potential threat level” for rinzimetostat.
- In notes issued Sunday and quoted by BioSpace, Leerink said JNJ-6143 “could be a game changer for the treatment of prostate cancer” and that its PSA responses “look better than most therapies in development in the same setting”.
- We found no ORIC statement on the J&J data. Writing while ORIC was down 22%, TIKR’s author argued that the decline looked excessive, noting that ORIC has a Phase 3 trial under way and cash to reach its readout.
What happened
ORIC lost about a third of its value in one session while the broader market rose.
- ORIC opened at $13.10 and closed at $8.96, down about 32%, according to Stock Analysis. Using the 103.65 million shares ORIC reported outstanding on July 27, the decline erased an estimated $0.44 billion from a pre-drop market value of about $1.37 billion.
- The broader market rose: AP reported gains of 0.7% for the S&P 500 and 0.8% for the Nasdaq Composite.
- ORIC issued releases on Oct 23 covering enozertinib, its lung cancer drug, and rinzimetostat findings from laboratory studies and patient samples. The enozertinib poster was scheduled for presentation on Monday. We found no Oct 26 release or filing.
- J&J is also an ORIC partner. Since 2024, it has supplied its drug apalutamide for an ORIC study combining it with rinzimetostat, under an agreement that gives J&J no rights to rinzimetostat, ORIC’s filings show.
J&J’s data in more detail
J&J’s results come from a small, short study, and the 75% response figure covers only the patients whose tumors could be measured.
- The 16 measurable patients were part of a 38-patient group on the 50 mg dose. Their responses were confirmed: tumor shrinkage of at least 30% held on a later scan.
- PSA, a blood marker of prostate cancer, fell by at least half in 77% of the 38 patients, including 48% whose PSA fell by at least 90%, J&J reported.
- Patients had received a median of four prior treatments; these included chemotherapy and radioactive medicines that target a protein called PSMA on prostate cancer cells, J&J said. Median follow-up was 5.6 months, and 71% were still on treatment.
- The most common treatment-related side effects were higher cholesterol, nausea and higher triglycerides. One patient of 38 stopped treatment because of side effects, J&J said.
- JNJ-6143 works differently from rinzimetostat. J&J says it links the androgen receptor, the hormone receptor that drives prostate cancer, to BRD4, a protein cells need to survive, which J&J says triggers the cancer cell’s death. Rinzimetostat blocks PRC2, a protein complex that helps tumors adapt to hormone therapy, according to ORIC.
The results can’t be compared directly
- J&J tested its drug alone in heavily treated patients. ORIC tests rinzimetostat with darolutamide in patients who have had abiraterone, a standard hormone pill.
- ORIC’s March results used a different yardstick: an estimated 84% five-month rate of survival without cancer progression on scans, with median follow-up of about five months. ORIC said nearly all treatment-related side effects were mild or moderate.
Does this change ORIC’s future?
What did NOT change
- ORIC’s own data and plans are unchanged. Himalayas-1 aims to enroll about 600 patients, with radiographic progression-free survival (the time until scans show the cancer worsening or the patient dies) as its main goal.
- ORIC said in August that its $387.6 million in cash and investments should last into the second half of 2028, beyond the trial’s expected main readout.
What DID change
- Rinzimetostat now faces a rival from a much larger company whose early data Leerink called “immaculate”. J&J’s drug is at an earlier stage of testing, and it is not yet known whether J&J will test it in the earlier-stage patients ORIC is targeting.
Our read
No new clinical data on rinzimetostat were reported on Monday; what changed is the competitive picture Leerink described. ORIC’s anticipated program update may provide more information about rinzimetostat, but separate trials cannot establish which drug is better.
What to watch next
- 2H 2026
- ORIC's rinzimetostat program update, anticipated in the second half of 2026.
- Ongoing
- Enrollment in Himalayas-1, ORIC's roughly 600-patient Phase 3 trial of rinzimetostat with Bayer's darolutamide.
- Ongoing
- J&J's Phase 2 study of JNJ-6143 at 50 mg, and any move into earlier-stage patients, where rinzimetostat is being tested.
Quick questions
Did ORIC announce anything on Oct 26?
We found no Oct 26 release or filing in the company lists checked for this article. ORIC had issued two ESMO releases on Oct 23, on enozertinib and on rinzimetostat laboratory and patient-sample findings, and its enozertinib poster was scheduled for presentation on Monday.
Is J&J's drug better than rinzimetostat?
That can't be told yet. The two drugs were tested in different patients, measured on different yardsticks, and neither has randomized results. J&J's data come from a small early study with about six months of follow-up.
Can ORIC keep funding its Phase 3 trial?
ORIC said in August that its $387.6 million in cash and investments should fund operations into the second half of 2028, past the expected main readout of its first rinzimetostat Phase 3 trial.
Updates
- : Corrected the valuation snapshot: market value now uses common shares outstanding (103.7 million on the 10-Q cover page, Jul 27, 2026), our standard basis, instead of 108.1 million shares including pre-funded warrants; market value $929M (was $969M) and enterprise value recalculated. Prices and dates unchanged.
About ORIC Pharmaceuticals: Website (external site)Investor relations (external site)SEC filings (external site)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.